US2020046818A1PendingUtilityA1

Yeast-based immunotherapy for chordoma

53
Assignee: GLOBEIMMUNE INCPriority: Mar 19, 2013Filed: Oct 25, 2019Published: Feb 13, 2020
Est. expiryMar 19, 2033(~6.7 yrs left)· nominal 20-yr term from priority
Inventors:Timothy C. RodellDavid ApelianClaudia M. PalenaJeffrey Schlom
A61P 35/04A61P 35/00A61P 43/00A61K 2039/521A61K 2039/545Y02A50/489A61K 39/0011A61K 39/00A61K 38/16Y02A50/30A61K 36/06
53
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Disclosed are methods of the treatment or prevention of chordoma which include the step of administering a yeast-based immunotherapeutic composition. The yeast-based immunotherapeutic composition preferably comprises a Brachyury antigen.

Claims

exact text as granted — not AI-modified
1 .- 17 . (canceled) 
     
     
         18 . A method to prevent chordoma, delay the onset of chordoma, or improve the outcome of chordoma in an individual who has a history of familial chordoma, comprising administering to the individual an immunotherapeutic composition comprising:
 a) a yeast vehicle; and   b) a cancer antigen comprising at least one Brachyury antigen;   wherein, at the time of administering, the individual has not been diagnosed with chordoma.   
     
     
         19 . The method of  claim 18 , wherein the Brachyury antigen is full-length human Brachyury. 
     
     
         20 . The method of  claim 18 , wherein the Brachyury antigen is not full-length Brachyury. 
     
     
         21 . The method of  claim 18 , wherein the Brachyury antigen has an amino acid sequence represented by SEQ ID NO:6, SEQ ID NO:18 or SEQ ID NO:2, or an amino acid sequence that is at least 95% identical to SEQ ID NO:6, SEQ ID NO:18 or SEQ ID NO:2. 
     
     
         22 . The method of  claim 18 , wherein the Brachyury antigen comprises from at least position 1 or 2 to between position 255 and the C-terminus of SEQ ID NO:6, SEQ ID NO:18 or SEQ ID NO:2. 
     
     
         23 . The method of  claim 18 , wherein the Brachyury antigen comprises from at least position 1 or 2 to between position 430 and the C-terminus of SEQ ID NO:6, SEQ ID NO:18 or SEQ ID NO:2. 
     
     
         24 . The method of  claim 18 , wherein the Brachyury antigen comprises positions 246 to 254 of SEQ ID NO:6, SEQ ID NO:18 or SEQ ID NO:2. 
     
     
         25 . The method of  claim 18 , wherein the Brachyury antigen comprises SEQ ID NO:6, positions 2-435 of SEQ ID NO:6, or an amino acid sequence that is at least 95% identical to SEQ ID NO:6. 
     
     
         26 . The method of  claim 18 , wherein the Brachyury antigen comprises SEQ ID NO:18, positions 2-435 of SEQ ID NO:18, or an amino acid sequence that is at least 95% identical to SEQ ID NO:18. 
     
     
         27 . The method of  claim 18 , wherein the Brachyury antigen comprises SEQ ID NO:2, positions 2-435 of SEQ ID NO:2, or an amino acid sequence that is at least 95% identical to SEQ ID NO:2. 
     
     
         28 . (canceled) 
     
     
         29 . (canceled) 
     
     
         30 . (canceled) 
     
     
         31 . The method of  claim 18 , wherein the Brachyury antigen has an amino acid sequence represented by SEQ ID NO:8, or an amino acid sequence that is at least 95% identical to SEQ ID NO:8. 
     
     
         32 . The method of  claim 18 , wherein the Brachyury antigen has an amino acid sequence represented by SEQ ID NO:20, or an amino acid sequence that is at least 95% identical to SEQ ID NO:20. 
     
     
         33 . The method of  claim 18 , wherein the yeast vehicle is a whole inactivated yeast. 
     
     
         34 . (canceled) 
     
     
         35 . The method of  claim 33 , wherein the whole yeast is heat-inactivated. 
     
     
         36 . The method of  claim 18 , wherein the yeast vehicle expresses the antigen. 
     
     
         37 . (canceled) 
     
     
         38 . (canceled) 
     
     
         39 . The method of  claim 18 , wherein the yeast is from  Saccharomyces cerevisiae.    
     
     
         40 . The method of  claim 18 , wherein the composition is formulated in a pharmaceutically acceptable excipient suitable for administration by injection of a subject. 
     
     
         41 . The method of  claim 18 , wherein the subject is administered the immunotherapeutic composition in a dose from about 0.1 Y.U. to about 100 Y.U. 
     
     
         42 . (canceled) 
     
     
         43 . (canceled) 
     
     
         44 . The method of  claim 18 , wherein the immunotherapeutic composition is administered weekly. 
     
     
         45 . The method of  claim 18 , wherein the immunotherapeutic composition is administered every other week. 
     
     
         46 . The method of  claim 18 , wherein the immunotherapeutic composition is administered monthly. 
     
     
         47 . The method of  claim 18 , wherein the immunotherapeutic composition is administered weekly for 5 weeks followed by monthly. 
     
     
         48 . The method of  claim 18 , wherein the immunotherapeutic composition is administered at two week intervals for 7 rounds of treatment, followed by monthly. 
     
     
         49 . The method of  claim 18 , wherein the immunotherapeutic composition is administered at more than one site on the individual to form a single dose. 
     
     
         50 . The method of  claim 18 , wherein the immunotherapeutic composition is administered concurrently with another therapy for cancer. 
     
     
         51 . (canceled) 
     
     
         52 . (canceled)

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.